Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is projected to achieve organic sales growth of 6.0-7.0% through 2025, with consensus estimates suggesting total revenue could reach approximately $44.69 billion, reflecting a 6.4% year-over-year increase. The company is experiencing robust growth across several key segments, including a notable 13.7% increase in its Electrophysiology business and double-digit growth in its Diabetes and Structural Heart portfolios. Furthermore, Abbott has a solid financial foundation, exemplified by its consistent dividend increases over the last 50 years and a strong balance sheet that positions it well for potential mergers and acquisitions.

Bears say

The financial outlook for Abbott Laboratories is negatively impacted by ongoing challenges related to Covid-19 testing, which saw a substantial decline in sales, falling from $265 million in Q3'24 to $69 million in Q3'25. Additionally, macroeconomic pressures, including inflation and foreign exchange fluctuations, combined with underwhelming performance in key markets such as China and slower-than-expected revenue from new medical products, further hinder growth prospects. Abbott's reliance on international sales, coupled with competitive pressures in the continuous glucose monitoring market, poses additional risks to the company's revenue stability and overall performance.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Nov 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.